F. Piscaglia, C. Nolsøe, C. Dietrich, D. Cosgrove, O. Gilja, M. B. Nielsen, T. Albrecht, L. Barozzi, M. Bertolotto, O. Catalano, M. Claudon, D. Clevert, J. Correas, M. D’Onofrio, F. Drudi, J. Eyding, M. Giovannini, M. Hocke, A. Ignee, E. Jung, A. Klauser, N. Lassau, E. Leen, G. Mathis, A. Saftoiu, G. Seidel, Paul S. Sidhu, G. T. Haar, D. Timmerman, H. Weskott
2011.8.26ULTRASCHALL IN DER MEDIZIN
tlooto Summary
When chemotherapy is successful, the lesion becomes almost non-enhancing on CEUS with absence of any intra-nodular vessels or microcirculation, seen early, paralleling the PET response.
Abstract
which has been found to be 90% sensitive and 100% specific compared to CT with respect to lesion detection in lymphoma patients [93]. In a retrospective study on splenic metastases, CEUS increased the detection rate by 38% [94]. Lesions found in patients with solid organ or haematological malignancies require whole-body imaging using CT and/or PET [95], but CEUS can be useful if they are inconclusive, particularly to rule out lesions when PET shows “ non-specific uptake ” . Finally, CEUS can be used in patients with splenic malignancies to monitor their response to treatment. When chemotherapy is successful, the lesion becomes almost non-enhancing on CEUS with absence of any intra-nodular vessels or microcirculation. These findings are seen early, paralleling the PET response. Long-term follow-up shows progressive dis-appearance of the lesions.
Citation format
PISCAGLIA, F., et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): Update 2011 on non-hepatic applications. ULTRASCHALL IN DER MEDIZIN, 2011, 33: 33–59.